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Abstract 
Adenosine A1 receptors (A1ARs) are promising imaging biomarkers and targets for the treatment of 
stroke. Nevertheless, the role of A1ARs on ischemic damage and its subsequent neuroinflammatory 
response has been scarcely explored so far. 
Methods: In this study, the expression of A1ARs after transient middle cerebral artery occlusion 
(MCAO) was evaluated by positron emission tomography (PET) with [18F]CPFPX and 
immunohistochemistry (IHC). In addition, the role of A1ARs on stroke inflammation using 
pharmacological modulation was assessed with magnetic resonance imaging (MRI), PET imaging with 
[18F]DPA-714 (TSPO) and [18F]FLT (cellular proliferation), as well as IHC and neurofunctional studies. 
Results: In the ischemic territory, [18F]CPFPX signal and IHC showed the overexpression of A1ARs in 
microglia and infiltrated leukocytes after cerebral ischemia. Ischemic rats treated with the A1AR agonist 
ENBA showed a significant decrease in both [18F]DPA-714 and [18F]FLT signal intensities at day 7 after 
cerebral ischemia, a feature that was confirmed by IHC results. Besides, the activation of A1ARs 
promoted the reduction of the brain lesion, as measured with T2W-MRI, and the improvement of 
neurological outcome including motor, sensory and reflex responses. These results show for the first 
time the in vivo PET imaging of A1ARs expression after cerebral ischemia in rats and the application of 
[18F]FLT to evaluate glial proliferation in response to treatment. 
Conclusion: Notably, these data provide evidence for A1ARs playing a key role in the control of both 
the activation of resident glia and the de novo proliferation of microglia and macrophages after 
experimental stroke in rats. 
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Introduction 
Cerebral ischemia triggers an acute increase in 
the concentration of purines (adenosine 5’- 
triphosphate-ATP and adenosine) that act as 
extracellular signaling molecules through a large 
variety of metabotropic P1 adenosine receptors (A1, 
A2A, A2B and A3), metabotropic P2Y and ionotropic P2X 
purinoreceptors [1, 2]. Adenosine receptors are 
expressed in the central nervous system, where they 
play a crucial role in a wide variety of physiological 









activity and vasodilation, among others [3, 4]. In 
addition, adenosine receptors have shown to be 
broadly expressed in both the innate and adaptive 
immunity, suggesting its control on the neuro-
inflammatory response [5]. Following ischemic brain 
injury, A1 adenosine receptors (A1ARs) modulate the 
release of IL-10 by immune cells, and the infusion of 
adenosine to the rat brain has shown protective effects 
reducing the infarct volume and improving the 
neurological outcome [6-10]. The temporal evolution 
of the expression of A1ARs after cerebral ischemia 
remains unknown and hence, the use of in vivo 
imaging modalities would be extremely helpful to 
gain knowledge on their expression and the 
protective role that they might play. During the last 
two decades, radiotracers such as 8-cyclopentyl-3-(3- 
[18F]fluoropropyl)-1-propylxanthine ([18F]CPFPX) 
have been developed for non-invasive positron 
emission tomography (PET) imaging of adenosine 
A1ARs in both human and rodent living brains [11, 
12]. [18F]CPFPX is a fluorinated analogue of 
8-cyclopentyl-1,3-dipropylxanthine (DPCPX), 
considered as the prototypical A1ARs antagonist due 
to its high selectivity and affinity for these receptors 
[13]. In addition, [18F]CPFXP has shown rapid blood 
brain barrier penetration, a cerebral binding 
proportional to the distribution of these receptors and 
a reproducible and reliable non-invasive 
quantification of A1AR density in the rat brain [12, 14]. 
Nevertheless, although PET imaging studies have 
reported alterations of A1AR density in neurological 
diseases [15-18], the role of these receptors on 
neuroinflammation, as revealed by nuclear imaging is 
still largely unknown. For this reason, this study aims 
to investigate the relationship of A1ARs with the 
neuroinflammatory reaction that follows stroke using 
multimodal imaging methods, immunohisto-
chemistry and neurofunctional evaluation after 
cerebral ischemia in rats. Ischemic rats treated with 
the selective A1AR antagonist (DPCPX) and the highly 
selective agonist (ENBA) were subjected to PET 
studies with [18F]DPA-714, an specific radioligand for 
the translocator protein (18kDa) (TSPO), and [18F]FLT 
for the evaluation of microglia/macrophage 
activation and proliferation [19-23]. TSPO over-
expression has been used as a surrogate marker for 
inflammatory activation after ischemia [20, 24], while 
a recent work form our group has demonstrated that 
[18F]FLT PET is able to detect proliferative 
inflammatory cells in the ischemic area after stroke 
[25]. Finally, the pharmacological modulation of 
A1ARs and its effects on brain damage was studied 
with magnetic resonance imaging (MRI) and 
neurological evaluation. 
The results reported here provide novel 
information about the role of A1ARs on stroke 
outcome and the subsequent inflammatory reaction in 
rats. In vivo imaging of the therapeutic and diagnostic 
potential of adenosine receptors is a promising 
strategy for stroke care, since adenosine signaling 
exerts control on the ischemic damage and neuro-
inflammation after cerebral ischemia [26]. Hence, the 
establishment of novel biomarkers such as adenosine 
receptors can contribute to accelerate the 
development of novel therapies for stroke [27]. 
Materials and Methods 
Cerebral ischemia in rats 
8-weeks old -male Sprague-Dawley rats (n = 85; 
304 ± 7.1 g body weight; Janvier, France) were used 
for both non-invasive imaging, metabolism and 
immunohistochemical studies. Animal experimental 
protocols and relevant details regarding welfare were 
approved by our institutional animal care and use 
committee (IACUC) and local authorities (Diputación 
Foral of Guipuzcoa) and were conducted in 
accordance with the ARRIVE guidelines and 
Directives of the European Union on animal ethics 
and welfare. All studies were conducted in our 
AAALAC certified SPF facilities. 
Rats were anaesthetized with 2.5% isoflurane in 
100% O2 and the right common, external, and internal 
carotid arteries were exposed through a ventral 
cervical midline incision. After electrocoagulation, the 
external carotid artery was ligated and cut 3-5 mm 
distal to the bifurcation. The pterygopalatine artery 
was ligated, and micro-clips were placed across both 
the common and external carotid arteries. A 2.6-cm 
length of 4–0 monofilament nylon suture (Sutures 
Aragó, Barcelona) heat-blunted at the tip was 
introduced into the external carotid artery through a 
puncture and gently advanced into the internal 
carotid artery and circle of Willis until the origin of 
the MCA was reached. During occlusion, animals 
were allowed to recover in their cages for 80 min. 10 
min before the end of the 90-min occlusion, animals 
were re-anaesthetized, the filament and the clip of the 
common carotid artery were gently removed and rats 
were kept in their cages with free access to food and 
water. 
Experimental set-up and treatments 
Ischemic rats were subjected to T2-weighted 
(T2W) MRI scans at 24 h after reperfusion to select rats 
presenting cortico-striatal infarction for inclusion in 
the PET studies. 7 rats were repeatedly scanned by 
PET before reperfusion (day 0) and at 1, 3, 7, 14, 21 
and 28 days after ischemic onset to evaluate the 
binding of A1ARs (Figure 1A). Subsequently, a group 
of 6 rats were subjected to MRI-T2W and Dynamic 





Contrast Enhanced (DCE)-MRI to evaluate brain 
lesion, the blood-brain barrier (BBB) disruption 
(BBBd) and radio-HPLC for metabolite analysis of 
[18F]DPCPX at control and days 1 and 3 after ischemia 
(Figure 1B). During 6 consecutive days, starting at day 
1 following MCAO, a first group of 14 rats was treated 
daily with intraperitoneal (i.p.) administration of 
8-cyclopentyl-1,3-dipropylxanthine (DPCPX, selective 
A1AR antagonist; 0.1 mL; 1.25 mg/kg), a second 
group of 12 rats was treated daily with i.p. 
administration of (±)-5'-chloro-5'-deoxy-ENBA 
(ENBA, highly selective A1AR agonist; 0.3 mL; 0.5 
mg/kg, i.p.) and a third control ischemic group of 18 
rats received the same daily volume of vehicle (saline) 
in a randomized and blinded fashion (Figures 1C and 
D). At day 7, all rats from these 3 groups were imaged 
with PET and MRI to determine the effect of DPCPX 
and ENBA on TSPO expression, glial proliferation, 
brain lesion volume and neurological outcome. Ex 
vivo ICH studies for TSPO and glial proliferation were 
also performed on those animals to validate PET 
imaging findings. Finally, 28 additional rats were 
used to perform IHC for A1ARs expression at 0, 1, 3, 7, 
14, 21 and 28 days after cerebral ischemia (n = 4 per 
time point). 
Magnetic resonance imaging 
T2W-MRI scans were acquired for rats subjected 
to the PET studies, to evaluate the infarction volume 
and to show the stroke evolution over the first month 
after ischemia onset. Furthermore, T2W-MRI scans 
were used to evaluate the infarction volume in treated 
and control rats before (day 1) and after the treatment 
(day 7). In addition, Dynamic Contrast Enhanced 
(DCE)-MRI scans at control and days 1-3 after 
ischemia were carried out to assess the influence of 
BBBd on the metabolite accumulation in the brain. 
Scans were performed in rats anaesthetized with 
isoflurane (2-2.5%) in a 30/70% mixture of O2/N2. 
Animals were placed into an MRI rat compatible 
holder and maintained in normothermia using a 
water-based heating blanket at 37 °C. To ensure 
animal welfare, temperature and respiration rate were 
continuously monitored while they remained in the 
MRI magnet, using a SAII M1030 system (SA 
Instruments, NY, USA). MRI in vivo studies were 
performed on a 7T horizontal bore Bruker Biospec 
USR 70/30 MRI system (Bruker Biospin GmbH, 
Ettlingen, Germany), interfaced to an AVANCE III 
console, and with a BGA12-S imaging gradient insert 
(maximal gradient strength 400 mT/m, switchable 
within 80 µs). Measurements were performed with a 
72 mm volumetric quadrature coil for excitation and a 
20 mm rat brain surface coil for reception. The 
imaging session started with the acquisition of a scout 
scan, which was used to plan the whole study 
focusing on the region of interest. T2W images were 
acquired with a Bruker’s RARE (Rapid Acquisition 
with Relaxation Enhancement) sequence (Effective TE 
= 40 ms, TR = 4400 ms, NA = 2; Matrix = 256 × 256 
points; FOV = 25.6 × 25.6 mm; spatial resolution = 100 
× 100 µm; 24 contiguous slices of 1 mm thickness 
covering the whole brain), which was used to 
quantify the volume of the lesion. 
 
 
Figure 1. Experimental set-up of the imaging and treatments studies. Temporal expression of A1ARs (A) and metabolite analysis of [18F]CPFPX after cerebral ischemia. 
Evaluation of the role of A1ARs receptors on glial activation (B) and proliferation (C). 





For the evaluation of BBB integrity, the tail vein 
was catheterized with a 24-gauge catheter for 
intravenous administration of the contrast agent 
(Multihance, 0.2 mmol/ml, 1 ml/Kg body weight). 
The BBBd was assessed using DCE-MRI, which 
allowed for differentiation between changes in 
vascular permeability and changes in the 
extravascular extracellular space (EES). The T1- 
weighted (T1W) DCE-MRI was acquired with a 
Bruker’s FLASH (Fast low-angle shot) sequence (TE = 
2.5 ms; TR = 31.25 ms; FA = 15º; NA = 1; NR = 200; 
Matrix = 128 × 128 points; FOV = 25.6 × 25.6 mm; 
spatial resolution = 200 × 200 µm; 5 slices of 1 mm 
thickness covering the ischemic lesion). This 
technique involves the serial acquisition in rapid 
succession of MR images (NR = 200) of a tissue of 
interest, being the ischemic lesion in this particular 
case, before and after the intravenous administration 
of Multihance, a gadolinium-based paramagnetic 
contrast agent. DCE-MRI allows for monitoring 
changes in the T1 relaxation rate of the tissue after the 
administration of gadolinium with repeated serial 
imaging using T1W images. 
Magnetic resonance imaging analysis 
For image analysis, regions of interest (ROIs) 
were manually defined using the open source 
software 3D Slicer (Version 4.8 http://www.slicer. 
org). The calculation of the lesion volume using MRI 
was carried out by summing the areas of infarcted 
regions showing hyperintense signals of all slices 
affected by the lesion. BBB Permeability (ktrans) maps 
were obtained from DCE-MRI images with 
DCE@urLAB software [28] in the lesion volume 
measured with T2W-MRI, using the Tofts Model with 
the following input parameters: T10 (tissue) 
pixel-wise obtained from acquired T1 maps, T10 
blood = 2070 ms [29], TR = 31.25 ms, FA = 15º, frame 
period = 2s, Nº frames = 200, contrast agent relaxivity 
= 4.24 mM-1 s-1, hematocrit = 0.43, Injection frame, 
Frames for IAUC= 5 and Arterial Input Function (AIF) 
as measured from a region of interest located at the 
carotid artery. 
Radiochemistry 
The production and quality control of 
[18F]DPA-714 (non-decay corrected radiochemical 
yield = 11 ± 2%; radiochemical purity > 95% at the 
time of injection; molar activity values 160-430 
GBq/µmol at the end of the synthesis) and [18F]FLT 
(non-decay corrected radiochemical yield = 8±1%; 
radiochemical purity > 95% at injection time) were 
carried out following established protocols in our 
laboratory [25]. [18F]-8-Cyclopentyl-3-(3-fluoro-
propyl)-1-propylxanthine ([18F]CPFPX) was produced 
following a previously described method with minor 
modifications. In brief, dried 18F was reacted with the 
appropriate precursor ((8-cyclopentyl-3-(3-tosyloxy-
propyl)-7-pivaloyloxymethyl-1-propylxanthinethe, 
prepared as previously described; [30] 2 mg) in 
dimethylsulfoxide (DMSO; 0.5 mL) (85 °C; 10 min). 
After cooling to room temperature, hydrolysis was 
conducted by addition of 2M sodium hydroxide 
aqueous solution (200 µL) (3 min, 30 °C). The reaction 
crude was neutralized with acetic acid (7 mmol), 
acetonitrile/water (1 mL; 60/40, v/v) was added and 
the mixture was purified by HPLC using a VP125/10 
Nucleosil 100-7 C18 column (Macherey-Nagel, Düren, 
Germany) as the stationary phase and acetonitrile/ 
water (60/40, v/v) as the mobile phase (flow rate = 7 
mL/min). The desired fraction (tR = 11–12 min) was 
collected, diluted with water (40 mL), and 
reformulated using a C-18 cartridge (Sep-Pak® Plus, 
Waters, Milford, MA, USA). The resulting ethanol 
solution (1 mL) was diluted with physiologic saline 
solution (9 mL) and filtered through 0.22 µm filter to 
yield the tracer was ready for injection. Chemical and 
radiochemical purity were determined by HPLC and 
co-elution with reference standard, prepared as 
previously described, [30] using a Mediterranean C18 
column (4.6 × 250 mm, 5 µm; Teknokroma, Spain) as 
the stationary phase and aqueous KH2PO4 solution 
(3.3 g/L)/acetonitrile (30/70, v/v) as the mobile 
phase at a flow rate of 1 mL/min (tR = 4.5 min). 
Non-decay corrected radiochemical yield was 17 ± 
3%. Radiochemical purity was always > 95% at the 
time of injection, and molar activity values were 
within the range 260-540 GBq/µmol at the end of the 
synthesis. 
Positron emission tomography scans and data 
acquisition 
PET scans were performed using an eXplore 
Vista PET-CT camera (GE Healthcare, Waukesha, WI, 
USA). Scans were performed in rats anaesthetized 
with 2-2.5% of isoflurane in 100% O2 at a constant time 
of day in order to avoid changes in receptor 
expression due to circadian rhythmicity. Animals 
were placed into a rat holder compatible with the PET 
acquisition system and maintained in normothermia 
using a water-based heating blanket at 37 °C. To 
ensure animal welfare, temperature and respiration 
rate were continuously monitored while they 
remained in the PET camera, using a SAII M1030 
system (SA Instruments, NY, USA). The tail vein was 
catheterized with a 24-gauge catheter for intravenous 
administration of the radiotracer. For longitudinal 
assessment of A1ARs (radiotracer: [18F]CPFPX), rats 
were scanned before and during the following month 
after ischemia. The radioactivity (min-max, 





35.52-81.31 MBq; 0.11-1.76 nmol; Table S1) was 
injected concomitantly with the start of the PET 
acquisition. During the first hour dynamic images of 
the brain were acquired for 60 min using 31 frames (3 
× 5, 3 × 10, 3 × 15, 3 × 30, 4 × 60, 4 × 120, 5 × 180, 6 × 
300 s) in the 400–700 keV energetic window. For 
evaluation of treatments on TSPO binding after 
ischemia, [18F]DPA-714 (min-max, 40.70-87.69 MBq; 
0.21-1.80 nmol; Table S2) was injected at the start of 
the PET acquisition and dynamic brain images were 
acquired for 30 min using 23 frames (3 × 5, 3 × 15, 4 × 
30, 4 × 60, 4 × 120, 5 × 180 s). Finally, [18F]FLT (min- 
max, 48.33-60.81 MBq; Table S3) was used to evaluate 
glial proliferation after ischemia. After the uptake 
period of 30 min, rats were anesthetized and placed 
on the PET for 30 min brain static acquisition. After 
each PET scan, CT acquisitions were also performed 
(140 mA intensity, 40 kV voltage), to provide 
anatomical information of each animal as well as the 
attenuation map for the later PET image 
reconstruction. Dynamic and static acquisitions were 
reconstructed (decay and CT-based attenuation 
corrected) with filtered back projection (FBP) using a 
Ramp filter with a cutoff frequency of 0.5 mm-1. 
Positron emission tomography image analysis 
PET images were analyzed using PMOD image 
analysis software (Version 3.5, PMOD Technologies 
Ltd, Zurich, Switzerland). For the analysis of PET 
signal, both PET images and an MRI (T2W) rat brain 
template from Pmod were separately manually 
co-registered to the CT of the same animal to generate 
a spatial normalization. Subsequently, MRI brain 
template was automatically co-registered to PET 
images. Two type of Volumes of Interest (VOIs) were 
established as follows: (1) A first set of VOIs was 
defined to study the whole brain [18F]CPFPX, 
[18F]DPA-714 and [18F]FLT PET signals. Whole brain 
VOIs were manually drawn in both the entire 
ipsilateral and contralateral hemispheres on slices of 
the MRI (T2W) rat brain template from the PMOD 
software. (2) A second set of VOIs was automatically 
generated in the cerebral cortex and the striatum by 
using the regions proposed by the PMOD rat brain 
template, to study the evolution of [18F]CPFPX PET 
signal in these specific regions in both the ipsilateral 
and contralateral cerebral hemispheres. For dynamic 
PET scans, the last three ([18F]CPFPX) or five 
([18F]DPA-714) frames were used to calculate 
radiotracers uptake during the last 15 min. For static 
PET scans, the 30 min frame was used to quantify the 
[18F]FLT uptake. Average values in each ROI were 
determined and expressed as percentage of injected 
dose per cubic centimeter (%ID/cc). 
Metabolite analysis 
Rats were injected intravenously (tail vein) with 
of [18F]DPCPX (76 ± 12 MBq) under a general 
anesthesia (2–2.5% isoflurane in pure 100%). At t = 60 
min, blood samples (ca. 500 µL) were obtained by 
cardiac puncture and animals were immediately 
perfused with heparinized saline solution. After 
complete perfusion, the brain was harvested. Blood 
samples were processed to separate the plasma, 
which was diluted with an equal volume of 
acetonitrile. After mixing vigorously for 20 s, samples 
were centrifuged at 2000 g for 4 min. The liquid phase 
was separated from the precipitate by decantation 
and was injected into the HPLC system equipped 
with a radioactivity detector (Gabi, Raytest), and 
using a Mediterranea C18 column (4.6 x 150 mm, 5 
µm; Teknokroma, Spain) as the stationary phase and 
aqueous KH2PO4 solution (3.3 g/L) (A)/acetonitrile 
(B) as the mobile phase (flow rate = 1 mL/min), with 
the following gradient: t = 0 min, 90% A; t = 1 min, 
90% A; t = 10 min, 10% A; t = 14 min, 10% A; t = 15 
min, 90% A; t = 19 min, 90% A (retention time of 
[18F]DPCPX: 9.2 min). For the determination of 
metabolites in the brain, the organ was divided in two 
hemispheres, which were separately homogenized in 
a glass homogenizer tube. Acetonitrile in ultrapure 
water (1:1; 500 µL) was added, the homogenate 
centrifuged (2000 g, 5 min at room temperature) and 
the supernatant analyzed by HPLC as above. In all 
cases, the percentage of non-metabolized parent 
compound was calculated as the ratio between the 
area under the peak corresponding to [18F]DPCPX, 
and the sum of the areas of all peaks in the 
chromatogram. 
Immunohistochemistry and cell counting 
Immunohistochemistry staining was carried out 
at day 0 and at 1, 3, 7, 14 and 28 days after ischemia 
and at day 7 in animals treated with DPCPX, Vehicle 
and ENBA. The brain was removed, frozen and cut in 
5-μm-thick sections in a cryostat. Sections were fixed 
in 4% paraformaldehyde during 15 min, washed with 
phosphate-buffered saline (PBS) and incubated 5 min 
in NH4Cl, following by two PBS rinse and 
methanol-acetone (1:1) permeabilization during 5 min 
at -20 ºC. After PBS washing, samples were saturated 
with a solution of bovine serum albumin (BSA) 
5%/Tween 0.5% in PBS during 15 min at room 
temperature, and incubated during 2 h at room 
temperature with primary antibodies BSA 
(5%)/Tween (0.5%) in PBS. The first set of sections 
were stained with for A1AR with rabbit anti-rat A1 
(1:300; Alomone Labs, Israel) and for CD11b with 
mouse anti-rat CD11b (1:300; Serotec, Raleigh, NC, 
USA). The second set of sections were stained for 





TSPO with a rabbit anti-rat TSPO (NP155, 1:1000) and 
for CD11b. Finally, the third set of sections were 
stained for Ki67 with rabbit anti-rat Ki67 (1:400, 
AbCam, Cambridge, UK) and CD11b. Sections were 
washed (3 × 10 min) in PBS and incubated for 1 h at 
room temperature with secondary antibodies Alexa 
Fluor 488 goat anti-rabbit IgG and Alexa Fluor 594 
goat anti-mouse IgG (Molecular Probes, Life 
Technologies, Madrid, Spain, 1:1000) in BSA 
5%/Tween 0.5% in PBS, washed again (3 × 10 min) in 
PBS, and mounted with a prolong antifade kit with or 
without DAPI in slices (Molecular Probes Life 
Technologies, Madrid). Standardized images 
acquisition was performed with the Panoramic MIDI 
II automated digital slide scanner (3DHistech Ltd., 
Hungary) for A1AR, the Axio Observer Z1 (Zeiss, Le 
Pecq, France) for TSPO and the Leica SP8 microscope 
(Hospitalet de Llobregat, Spain) for Ki67 imaging. 
Cells were manually counted in ten representative 
and different fields at 40 × and 100 × magnifications 
by using Image J (Version 2.0.0-rc-69/11.52p, NIH) 
software. 
Neurological assessment 
The assessment of neurological outcome induced 
by cerebral ischemia was based on a previously 
reported 9-neuroscore test [31]. This test is a global 
neurological assessment that was developed to 
measure neurological impairments following stroke 
and assesses a variety of motor, sensory and reflex 
responses. Before imaging evaluations, four 
consecutive tests were performed at days 1 and 7 after 
ischemia in treated and control rats as follows: (a) 
spontaneous activity (moving and exploring = 0, 
moving without exploring = 1, not moving = 2); (b) 
left drifting during displacement (none = 0, drifting 
only when elevated by the tail and pushed or pulled = 
1, spontaneous drifting = 2, circling without 
displacement or spinning = 3), (c) parachute reflex 
(symmetrical = 0, asymmetrical = 1, contralateral 
forelimb retracted = 2), and (d) resistance to left 
forepaw stretching (stretching not allowed = 0, 
stretching allowed after some attempts = 1, no 
resistance = 2). Total score could range from 0 
(normal) to a 9 (highest handicap) point-scale. 
Statistical analyses 
For longitudinal PET imaging studies, values of 
percentage of injected dose per cubic centimeter 
(%ID/cc) within each region and time point following 
cerebral ischemia were averaged and compared with 
the averaged values of every time point using 
repeated measures ANOVA followed by Tukey’s 
multiple-comparison tests for post-hoc analysis. For 
longitudinal neurological assessment, the 
neurological outcome at days 0 and 1 after cerebral 
ischemia were averaged and compared with the 
averaged values of every time point using the same 
statistical method used in PET studies. Cellular 
expression of microglial and infiltrated leukocytes/ 
A1ARs before (day 0) and at different days after 
ischemia were compared using one-way ANOVA 
followed by Tukey’s multiple-comparison tests for 
post-hoc analysis. For treatment studies, infarct 
volume and neurological score differences before 
(1day after MCAO) and after treatments (7 days after 
MCAO) were averaged and compared using two-way 
ANOVA with Sidak’s multiple comparison tests for 
post-hoc test. Additionally, the effects of the 
treatments in PET uptake, infarct volume, 
microglial/TSPO and microglial/Ki67 at day 7 after 
ischemia were compared using a one-way ANOVA 
followed by Bonferroni’s multiple-comparison tests 
for post hoc analysis. The level of significance was 
regularly set at P < 0.05. Statistical analyses were 
performed with GraphPad Prism version 8 software. 
Results 
Hyperintense regions of MRI-T2W images 
showed the formation of vasogenic edema as the 
result of the evolution of the brain ischemia at day 1 
after 90 min MCAO followed by the progression of 
the lesion at 3, 7, 14, 21 and 28 days after ischemic 
stroke (Figure 2A). The extent of brain damage was 
assessed using T2W MRI at 1 day after ischemia (mean 
± sd.: 326 ± 41 mm3, n = 7). PET images with 
normalized color scale illustrate the temporal 
expression and cerebral distribution of A1ARs with 
[18F]CPFPX in the rat brain at control and over the 
following month after ischemia stroke (Figure 2B). 
[18F]CPFPX after cerebral ischemia 
In vivo imaging of A1ARs was evaluated with the 
radiotracer [18F]CPFPX in the ipsilateral and 
contralateral whole brain, cerebral cortex and 
striatum before (control) (67.80 ± 8.14 MBq; 0.37 ± 0.34 
nmol) and at 1 (65.25 ± 13.11 MBq; 0.47 ± 0.29 nmol), 3 
(64.48 ± 7.55 MBq; 0.56 ± 0.48 nmol), 7 (68.77 ± 7.62 
MBq; 0.68 ± 0.58 nmol), 14 (66.37 ± 6.89 MBq; 0.61 ± 
0.57 nmol), 21 (61.58 ± 12.46 MBq; 0.56 ± 0.52 nmol) 
and 28 (67.76 ± 3.56 MBq; 0.53 ± 0.56 nmol) days after 
MCAO (Figure 3 and Table S1). In the ipsilateral 
whole brain, [18F]CPFPX showed a significant 
decrease at day 1 after ischemia in comparison to 
baseline (p < 0.05, Figure 3A). Subsequently, an 
increase of PET signal was detected at days 3 (p < 
0.001) and 7 (p < 0.05) with respect to day 1 after 
ischemia. The highest value was reached at day 3 after 
ischemia onset, compared with 14 (p < 0.01), 21 and 28 
days (p < 0.001). In addition, PET signal significantly 





decreased at 21 and 28 days with respect to day 7 and 
baseline levels (p < 0.01; Figure 3A). In the 
contralateral whole brain, [18F]CPFPX signal showed 
similar values along the different days evaluated 
(Figure 3B). [18F]CPFPX PET signal at day 0 (control) 
showed similar values (circa 0.5 %ID/cc) in both 
cerebral cortex and striatum evidencing similar 
distribution of A1ARs in the main brain regions 
affected by MCAO (Figure 3C and E). Similarly to the 
whole brain, ischemic cerebral cortex and striatum 
showed a significant decrease (p < 0.01 versus baseline 
values) followed by a significant PET signal peak at 
day 3 (p < 0.01, versus baseline values and day 14) and 
followed by a progressive decrease from days 7 to 28 
after cerebral ischemia. After the second week, PET 
values displayed similar values to those shown at day 
1 after cerebral ischemia (Figures 3C and E). Finally, 
the contralateral cerebral cortex and striatum 
displayed non-significant [18F]CPFPX PET signal 




Figure 2. Magnetic resonance imaging (MRI) (T2-weighthing (T2W)) and Positron 
emission tomography (PET) images of [18F]CPFPX before (day 0) and at days 1, 3, 7, 
14, 21 and 28 after cerebral ischemia in a representative rat. MRI-T2W (A) and 
co-registered [18F]CPFPX PET- MRI-T2W (B) axial images show the ischemic lesion 
evolution over one month after stroke onset. 
Metabolite analyses of [18F]CPFPX after 
MCAO 
The evaluation of the parent compound 
([18F]CPFPX) and its metabolites was carried out by 
radio-HPLC at 60 min after injection of [18F]CPFPX in 
both control and ischemic rats (Figure 4). Rats were 
subjected to T2W-MRI and DCE-MRI to evaluate the 
extension of the ischemic lesion and the BBBd at 
control and after ischemia (days 1 and 3), respectively, 
to evaluate the effect of BBB integrity on metabolite 
accumulation in ischemic brain (Figure 4A). These 
results showed a non-significant decrease of the 
volume of infarction at day 3 in relation to day 1 after 
MCAO (Figure 4B). Likewise, Ktrans values showed a 
non-significant increase of BBBd at day 3 in relation to 
control and day 1 after ischemia (Figure 4C). One 
major metabolite was detected as result of metabolism 
of [18F]CPFPX in both healthy and ischemic conditions 
with Radio-HPLC (Figure 4D). Both the metabolite 
and [18F]CPFPX were detected in blood and both brain 
hemispheres using the same rats subjected to MRI 
studies (Figure 4D). At 60 min after [18F]CPFPX 
administration, almost all the injected radiotracer was 
metabolized in blood at control (94.85% ± 0.07) and at 
days 1 (94.40% ± 0.56) and 3 (89.85% ± 4.17) after 
MCAO (Figure 4E). In contrary, this situation was 
reverted in the non-ischemic (contralateral) brain 
hemisphere showing a higher percentage of 
[18F]CPFPX in relation to metabolite at control (87% ± 
3.81) and at days 1 (89.15% ± 5.73) and 3 (93.25% ± 
0.92) after ischemia (Figure 4F). Finally, the ischemic 
hemisphere showed a slight decrease of [18F]CPFPX 
accumulation at day 1 (71.75% ± 12.37) and day 3 
(71.05% ± 5.02) in relation to control rats (85.65% ± 
4.03) (Figure 4G). Likewise, the metabolite content 
increased in the region of infarction at days 1 (28.25% 
± 12.37) and 3 (28.95% ± 5.02) in relation to control 
(14.35% ± 4.03) values (Figure 4G). Overall, these 
results showed that the metabolite accumulation in 
the ischemic brain was influenced by the disruption of 
BBB after MCAO (Figure 4C and G). 
Expression of purinergic A1ARs in microglia 
and infiltrated leukocytes after MCAO 
Immunofluorescence staining showed A1ARs 
expression in a heterogeneous population of 
inflammatory cells such as microglia and infiltrated 
leukocytes (macrophages and neutrophils) after 
cerebral ischemia (Figure 5). At day 0, the expression 
of A1ARs was observed mainly in purinergic neurons 
distributed in different cerebral regions (Figure 5A), 
followed by a sharp decline at day 1 in the region of 
infarction (Figure 5B). At day 3, CD11b positive cells 
with round morphology and multilobulated nucleus 
(neutrophils) co-localized with the cellular expression 





of A1ARs (in yellow; Figure 5C). Finally, A1ARs 
expression in microglia/macrophage with ameboid 
shape expressing CD11b (in yellow; Figure 5D) was 
observed at day 7. Hence, the number A1ARs/CD11b 
cells displayed a sharp significant increase at days 3 to 
7 in relation to days 0 and 1 followed by a decrease 
during the following weeks after reperfusion (p < 
0.001, Figure 5E). 
Time course of neurologic score after 
experimental stroke 
Neurofunctional impairment including sensory 
and motor deficits was evaluated with the 
9-neuroscore test before (control) and at 1, 3, 7, 14, 21 
and 28 days after MCAO (Figure 5F). Ischemic 
animals showed the major neurologic impairment at 1 
day after MCAO in relation to day 0 (control animals) 
followed by a progressive functional recovery over 
time. The neurological impairment showed significant 
increase versus that in the controls at days 1, 3, 7, 14, 
21, and 28 after ischemia (p < 0.001, Figure 5F). After 
day 3, rats showed a trend to a progressive functional 
recovery over time at days 7 (p < 0.01), 14, 21, and 28 




Figure 3. Time course of the progression of [18F]CPFPX PET signals (n = 7) before (day 0) and at different days after ischemia. %ID/cc of [18F]CPFPX was quantified in the entire 
ipsilateral cerebral hemisphere (A), contralateral hemisphere (B), ipsilateral cerebral cortex (C), contralateral cerebral cortex (D), ipsilateral striatum (E) and contralateral 
striatum (F). The upper right panel of each figure show the selected brain ROI for the quantification defined on an axial slice of a MRI (T2W) template. *p < 0.05 and **p < 0.01 
compared with day 3; #p < 0.05 and ##p < 0.01 compared with day 7; &p < 0.05 and &&p < 0.01 and &&&p < 0.01 compared with day 0. [18F]CPFPX signal show non-significant changes 
at different days after MCAO in the contralateral hemisphere. Values are presented as scatter dot blot (mean ± SD). 






Figure 4. Magnetic resonance imaging (MRI) (T2-weighthing (T2W)), Dynamic Contrast Enhanced (DCE) images and Radio-HPLC before (day 0) and at days 1 and 3 after 
cerebral ischemia. MRI-T2W and DCE-MRI axial images show the ischemic lesion and blood brain barrier disruption (BBBd) evolution during first 3 days after stroke onset (A). 
Infarct volume with MRI (T2W) (B), and BBBd with DCE-MRI (C) were evaluated at control (n = 2) and at days 1 (n = 2) and 3 (n = 2) after MCAO in rats. Chromatograms show 
[18F]CPFPX and metabolite formation in blood, contralateral and ipsilateral brain hemispheres at 60 min after radiotracer injection (D). % of metabolite and parent compound was 
evaluated in same animals subjected to MRI in blood (E), contralateral (F) and ipsilateral (G) cerebral hemispheres. Infarct volume and BBBd values show non-significant changes 
at different days after MCAO. Values are presented as scatter dot blot (mean ± SD). 






Figure 5. Immunofluorescent labeling of A1ARs (green), CD11b (red) and DAPI (blue) in the ischemic region, shown as merged channels and neurological outcome after 
ischemia. The data show the temporal evolution of A1ARs expression in microglia and infiltrated leukocytes (macrophages and neutrophils) expressing CD11b at day 0 (A), day 
1 (B), day 3 (C) and day 7 (D) after ischemia. The number of CD11b-reactive microglia and infiltrated leukocytes (n = 4) were measured at different time points in the infarcted 
brain hemisphere (E). The upper right panel of this figure show the selected brain ROI for the quantification defined on an axial slice of a MRI (T2W) template. The neurological 
score show an improvement over time (F). ***p < 0.01 compared with day 3; ###p < 0.01 compared with day 7; &&&p < 0.01 compared with day 0 and $$p < 0.01 and $$$p < 0.01 
compared with day 1. Scale bars, 10 and 20 µm. Values are presented as scatter dot blot (mean ± SD). 
 
Effect of A1ARs modulation on stroke 
outcome and microglial/macrophage 
activation 
The role of A1ARs on stroke evolution and 
inflammatory reaction was explored using MRI, PET, 
behavioral evaluation and immunohistochemistry 
after daily treatment (from day 1 to day 7) after 
MCAO with the selective A1AR antagonist (DPCPX), 
the highly selective A1AR (ENBA) and vehicle after 
MCAO. Infarct volumes measured by T2W-MRI at 
day 1 after ischemia, before the starting of treatments, 
was not significantly different among different 
experimental groups (Figure 6D). Infarct volumes at 
day 7 showed a significant decrease in ischemic 
treated animals with DPCPX, Vehicle and ENBA (p < 





0.05; p < 0.01; p < 0.001, Figure 6D) in comparison to 
day 1 (before the initiation of the treatments). 
Likewise, the activation of A1ARs with ENBA showed 
significant stroke infarction reduction at day 7 in 
relation to ischemic animals treated with DPCPX (p < 
0.05, Figure 6E). Additionally, the different 
experimental groups of animals presented similar 
neurological impairment before the start of the 
treatments (day 1) (Figure 6F). One week later, the 
neurological outcome showed a significant 
improvement in relation to day 1 after different 
treatments (p < 0.05; p < 0.001, Figure 6F) in 
comparison to day 1 (before the initiation of the 
treatments). Besides, the pharmacological activation 
of A1ARs with ENBA after ischemia displayed a 
significant reduction of the neurological outcome 
relative to vehicle-treated ischemic rats at day 7 after 
MCAO (p < 0.05, Figure 6F). The effect of 
pharmacologically modulation of A1ARs on 
microglial/macrophage activation was explored with 
PET imaging of TSPO using the radiotracer [18F]DPA- 
714 at day 7 after MCAO. All images were quantified 
in standard units (%ID/cc). Axial images with 
normalized color scale showed [18F]DPA-714 PET 
signal differences in DPCPX (66.92 ± 13.79 MBq; 0.99 ± 
0.59 nmol), Vehicle (72.10 ± 6.81 MBq; 0.84 ± 0.49 
nmol) and ENBA (71.29 ± 9.04 MBq; 0.82 ± 0.52 nmol) 
treated ischemic rats (Figure 6C and Table S2). 
Treatment with ENBA rendered a significant decrease 
of PET signal in the ischemic cerebral hemisphere in 
comparison to DPCPX and Vehicle treated MCAO 
rats (p < 0.05; p < 0.01, Figure 6G). Immuno-
fluorescence staining displayed TSPO over- 
expression (in green; Figure 7A) in CD11b+ cells after 
ischemia (in red; Figure 7B) in DPCPX, Vehicle and 
ENBA treated rats (Figure 7B). At day 7, TSPO over- 
expression co-localized with reactive microglia/ 
macrophages showing intense CD11b immuno-
reactivity in the ischemic lesion (in green and red; 
Figure 7C). The number of TSPO+/CD11b+ cells 
showed a significant decrease in treated ischemic rats 
with ENBA at day 7 after ischemia in comparison 
with DPCPX and Vehicle treated rats (p < 0.01; p < 
0.01, Figure 7D).  
Role of A1ARs modulation on 
microglial/macrophage proliferation 
The effect of A1ARs modulation on the 
proliferation of microglia and infiltrated macrophages 
was evaluated using PET and immunohistochemical 
studies after treatments with DPCPX, Vehicle and 
ENBA during the first week after MCAO. T2W-MRI 
evaluation showed similar infarct volumes at day 1 
after ischemia (before the start of treatments) among 
different experimental groups to avoid bias (Figure 
8A and C). The effects of the pharmacological 
modulation of A1ARs on the proliferation of 
microglial and infiltrated macrophages was evaluated 
using PET with the radiotracer [18F]FLT at day 7 after 
MCAO. Normalized PET images showed [18F]FLT 
PET signal in the region affected by the cerebral 
infraction in ischemic rats treated with DPCPX (52.84 
± 4.35 MBq) and Vehicle (53.66 ± 2.70 MBq) that was 
significantly decreased in ENBA (57.55 ± 2.19 MBq) 
treated rats at day 7 after MCAO (p < 0.05; p < 0.01, 
Figures 8B, 8D and Table S3). Immunohistochemical 
studies showed proliferative CD11b+ cells (in 
green-Ki67 and red-CD11b; Figures 9B and C) in 
DPCPX, Vehicle and ENBA ischemic treated rats. At 
day 7, ENBA treated animals displayed a significant 
reduction in the number of proliferating (Ki67+) 
microglia/macrophages in comparison with DPCPX 
and Vehicle treated rats (p < 0.05, Figure 9D and E). 
Discussion 
The present study showed the overexpression of 
A1ARs during neuroinflammation underlying 
experimental stroke using PET imaging with 
[18F]CPFPX and immunohistochemical studies. 
Moreover, the therapeutic modulation of A1ARs 
improved stroke outcome and declined both the 
activation and proliferation of microglia and 
macrophages with [18F]DPA-714 and [18F]FLT 
radioligands, respectively. 
In vivo and ex vivo overexpression of A1ARs 
after experimental stroke 
The in vivo distribution of [18F]CPFPX binding in 
the healthy human and rats brains were characterized 
by the distribution pattern of A1ARs in grey matter 
regions such as cortex and striatum, among others [11, 
12]. Hence, previously reported findings are 
consistent with the [18F]CPFPX PET uptake 
distribution in the healthy rat brain (before the 
induction of cerebral ischemia) observed in our work 
(day 0; Figure 2). In addition, metabolite analysis 
showed circa 90% of parent compound ([18F]CPFPX) 
in the healthy brain at 60 min after radioligand 
injection evidencing the stability and usefulness of 
[18F]CPFPX for in vivo PET imaging studies (Figure 4). 
During the first stages after ischemia, [18F]CPFPX 
PET signal displayed a significant decrease as a direct 
consequence of the massive neuronal death process 
during stroke (day 1; Figure 2). In fact, these results 
support those described by Nariai and colleagues who 
observed that the degree of decreased PET binging to 
A1ARs was a sensitive predictor of severe ischemic 
insult [32]. As a response to cellular stress during 
hypoxia and inflammation, adenosine controls 
pro-inflammatory and anti-inflammatory responses 





through A1ARs expressed in microglia and infiltrated 
macrophages in the central nervous system [33]. In 
addition, [18F]CPFPX PET imaging detected 
peritumoral changes in A1ARs density concomitantly 
with the high activation of glial cells in the vicinity of 
the glioma [34]. In the present study, A1AR expression 
with [18F]CPFPX was evaluated during the following 
month after MCAO in rats, to examine its relation 
with the neuroinflammatory reaction after cerebral 
ischemia. In the ischemic territory, [18F]CPFPX uptake 
showed up a sharp significant increase at days 3 and 7 
in relation to day 1 as a response to neuro-
inflammation followed by a progressive reduction of 
A1ARs expression from days 14 to 28 after ischemia 
due to cell death and resolution of the inflammatory 
response (Figures 2 and 3). Additionally, metabolite 
studies in ischemic rats at days 1 and 3 after MCAO 
showed similar cerebral accumulation of both 
[18F]CPFPX and metabolite despite PET imaging 
studies showed opposite uptake values at day 1 in 
relation to day 3 after ischemia (Figures 2 to 4). Hence, 
A1ARs expression changes observed with [18F]CPFPX 
PET cannot be attributed to radiotracer 
metabolization following cerebral ischemia. 
 
 
Figure 6. MRI-T2W and PET images of [18F]DPA-714 in DPCPX, vehicle and ENBA-treated ischemic rats. MRI (T2W) (A, B) and TSPO receptor PET signal (C) images of axial 
planes at the level of the ischemic lesion. Infarct volume with MRI (T2W) (D, E), neurological score (F) were evaluated at day 1 after ischemia (before the start of treatments) and 
at day 7 after MCAO in DPCPX (n = 7), vehicle (n = 7) and ENBA-treated (n = 6) rats. [18F]DPA-714 PET signal was quantified at day 7 after ischemia (G). *p < 0.05 compared 
with vehicle; #p < 0.05, ##p < 0.01 and ##p < 0.001 compared with day 1; $p < 0.05, compared with MCAO+DPCPX; &p < 0.05 and &&p < 0.01 compared with MCAO+ENBA. 
Values are presented as scatter dot blot (mean ± SD). 






Figure 7. Immunofluorescent labeling of TSPO (green) and CD11b (red) in the ischemic area, shown as two channels. The data show TSPO expression in microglia/macrophages 
at day 7 after MCAO in DPCPX (upper row), vehicle (middle row), and ENBA-treated rats (lower row). TSPO expression (A) in CD11b-reactive microglia/macrophages (B) 
decreases after MCAO in ENBA-treated rats in merged images of two immunofluorescent antibodies (C). The number of CD11b-reactive microglia/macrophages expressing 
TSPO was evaluated at day 7 after daily treatment with DPCPX (n = 7), Vehicle (n = 7) and ENBA (n = 6) (D). **p < 0.01 and ***p < 0.01 compared with MCAO+ENBA. Scale 
bars, 5 µm. Values are presented as scatter dot blot (mean ± SD). 
 
Figure 8. MRI-T2W and PET images of [18F]FLT in DPCPX, vehicle and ENBA-treated ischemic rats. MRI (T2W) (A) and glial proliferation PET signal (B) images of axial planes 
at the level of the ischemic lesion. Infarct volume with MRI (T2W) (C) at day 1 and [18F]FLT PET uptake (D) at day 7 after MCAO in DPCPX (n = 7), vehicle (n = 8) and 
ENBA-treated (n = 6) rats. *p < 0.05, **p < 0.01 compared with MCAO+ENBA. Values are presented as scatter dot blot (mean ± SD). 
 
Altogether, these findings are in agreement with 
previous PET studies of cholinergic (α7 and α4β2 
receptors) and glutamatergic (system xc-) signaling 
which showed overexpression of these receptors on 
glial cells during the first week after ischemia [27]. 
Therefore, altogether might suggest that [18F]CPFPX 
PET signal increase is linked to the neuro-
inflammatory reaction underlying stroke. To verify 
this hypothesis, the immunohistochemical 
characterization of A1ARs on glial cells was carried 
out during the following month after MCAO (Figure 
5). These results confirmed the overexpression of 
A1ARs in microglia and infiltrated macrophages 
(macrophages and neutrophils) at days 3 to 7 after 
MCAO. Therefore, these findings supported the 
evidence that the [18F]CPFPX signal increase after 





cerebral ischemia was mainly due to the A1ARs 
over-expression in CD11b positive cells (microglia 
and infiltrated macrophages). Likewise, the peak of 
A1ARs expression observed by PET imaging from day 
3 to 7 was consistent with the functional recovery 
observed in the ischemic rats (Figure 5F). 
Additionally, the profile of A1AR expression was in 
agreement with the temporal expression of some 
anti-inflammatory markers and cytokines such as 
CD206, YM1/2 and Arg1 after cerebral ischemia, as 
previously described by Hu and colleagues [35]. 
A1ARs activation improves stroke outcome 
and attenuates inflammatory activation 
Previously, the pharmacological activation of 
A1ARs with selective agonists has shown therapeutic 
potential attenuating ischemic brain damage after 
animal models of stroke [36, 37]. In addition, the 
activation of these receptors increased the IL10 
expression whereas KO mice lacking A1ARs have a 
reduced interleukin expression by immune cells after 
neonatal hypoxic ischemic brain injury [7]. In our 
study, we evaluated the modulatory effect of the 
antagonist DPCPX and the agonist ENBA on stroke 
outcome with MRI-T2W and neuroinflammatory 
reaction with [18F]DPA-714 PET following cerebral 
ischemia (Figure 6A to C). We showed a beneficial 
effect of ENBA on brain edema formation and 
neurofunctional evolution in relation to vehicle and 
DPCPX treated ischemic rats (Figure 6D to F). The 
improvement of stroke outcome at day 7 after daily 
treatment with ENBA was concomitant with the 
significant decrease of TSPO expression with 
[18F]DPA-714, supporting the role played by A1ARs 
on neuroinflammation after cerebral ischemia (Figure 
6G). Besides, ischemic rats treated with ENBA 
showed a significant decrease of CD11b positive cells 
expressing TSPO (Figure 7), confirming the results 
obtained with PET imaging using [18F]DPA-714. In 
fact, this is the first study using PET imaging to 
evaluate the modulatory effect of A1ARs on 
neuroinflammation after ischemia using TSPO as 
biomarker of reactive gliosis. Therefore, our results 
were supported by those studies showing the role of 
A1ARs in the morphological activation of microglia 
playing a tight control in microglia physiology [38, 
39]. In this sense, the chronic ingestion of caffeine, a 
well-known antagonist for A1ARs, displayed a 
systemic impact on the activation of microglia but not 
on their proliferation in the healthy brain [39]. In 
contrast, other studies confirmed the increase of 
microglial proliferation after simultaneous 
stimulation of both A1 and A2A receptors [40]. Thus, 
we evaluated the effect of A1AR modulation on glial 
proliferation with PET imaging after stroke to better 
answer this question. 
Effect of A1ARs modulation on microglia/ 
macrophage proliferation after ischemia 
Recently, we described a novel imaging method 
to quantify in vivo glial proliferation using PET with 
[18F]FLT [21]. This radiotracer is an analog of 
 
Figure 9. Immunofluorescent labeling of DAPI (blue), Ki67 (green) and CD11b (red) in the ischemic region, shown as three channels. The data show proliferative (Ki67+), 
microglia/macrophages (CD11b+) at day 7 after MCAO in DPCPX (upper row), vehicle (middle row), and ENBA-treated rats (lower row). Proliferative CD11b-reactive 
microglia/macrophages decrease after MCAO in ENBA-treated rats (see merged images) (D). The number of CD11b-reactive microglia/macrophages showing positive Ki67 was 
evaluated at day 7 after daily treatment with DPCPX (n = 5), Vehicle (n = 8) and ENBA (n = 6) (E). *p < 0.05 compared with MCAO+ENBA. Scale bars, 10 µm. Values are 
presented as scatter dot blot (mean ± SD).  
 





thymidine which is phosphorylated by thymidine 
kinase-1 (TK-1), an enzyme expressed during the 
DNA synthesis and up-regulated during the S phase 
of the cell cycle [41]. This study showed [18F]FLT 
signal increase in the ischemic lesion during the first 
week after MCAO that was in accordance with the 
increase of proliferative microglia/infiltrated 
macrophages [21]. In the current study, we have 
assessed the effect of A1ARs modulation with DPCPX 
and ENBA on microglia/macrophage proliferation 
using [18F]FLT PET after stroke (Figure 8). The 
activation of A1ARs with ENBA showed a significant 
decrease of cellular proliferation with [18F]FLT PET at 
day 7 after MCAO (Figure 8D). In addition, ischemic 
rats treated with ENBA showed a significant decrease 
of proliferative microglia/infiltrated macrophages 
(CD11b positive cells) expressing Ki67, a well-known 
marker for the evaluation of proliferation [42] (Figure 
9), confirming the results obtained with PET imaging 
using [18F]FLT. 
Summary and Conclusions 
In summary, multimodal imaging studies were 
carried out to decipher the role of A1ARs on 
neuroinflammatory reaction after cerebral ischemia in 
rats. The present findings showed that [18F]CPFPX 
PET signal increases in the ischemic hemisphere at 
day 3 after ischemia followed by a progressive decline 
afterwards. In addition, A1AR overexpression was 
identified in microglia and infiltrated leukocytes 
using immunohistochemistry. Finally, the activation 
of A1AR was able to induce ischemic damage 
protection and reduction of both reactive and 
proliferative microglia/macrophages after 
experimental stroke in rats. Altogether, our results 
provide novel knowledge regarding the control of 
A1AR on ischemic damage and inflammation that 
might contribute to the development of novel 
therapies for stroke. 
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